Johnson & Johnson (NYSE: JNJ) will present clinical data from two studies on its TECNIS PureSee intraocular lens at the American Society of Cataract and Refractive Surgery Annual Meeting from April 10-13 in Washington, DC.

The studies included 293 patients across 19 sites in Europe and Asia-Pacific, and 200 patients across nine U.S. sites. According to the company's press release, the TECNIS PureSee IOL is an Extended Depth of Focus lens that received FDA approval.

Results from the international study showed mean binocular uncorrected distance vision of 20/19 and intermediate and distance corrected vision of 20/26. The study reported that 91% of patients experienced little or no bothersome glare, 93% had minimal halos, and 92% had minimal starbursts. Spectacle independence was reported in 96% of patients for distance, 95% for intermediate, and 61% for near vision, with 93% patient satisfaction across all distances.

The U.S. prospective, randomized clinical trial compared the TECNIS PureSee IOL to a monofocal control lens. The study indicated the lens provided distance vision and intermediate vision compared to the monofocal control, with contrast sensitivity comparable to an aspheric monofocal IOL.

"The data presented at ASCRS 2026 confirms that TECNIS PureSee IOL provides patients with high contrast sensitivity and visual acuity across distances, with low levels of visual disturbances," said Paul Lisenby, Global Head of Research and Development, Vision, Johnson & Johnson.

The TECNIS PureSee IOL is indicated for primary implantation for visual correction of aphakia in adult patients with less than 1 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed.